Big Pharma Split Corp.
PRM.TO
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 452.90K | 459.70K | -28.70K | -29.10K | -211.10K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 175.80K | 178.40K | 498.70K | 505.80K | 4.15M |
| Change in Net Operating Assets | 6.20K | 6.30K | 3.60K | 3.60K | 0.00 |
| Cash from Operations | 635.00K | 644.40K | 473.60K | 480.30K | 3.93M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -12.20K | -12.20K | -403.30K | -403.30K | -2.26M |
| Issuance of Preferred Stock | 368.80K | 368.80K | 156.80K | 156.80K | 65.80K |
| Repurchase of Preferred Stock | -- | -- | 0.00 | 0.00 | -2.74M |
| Total Dividends Paid | -387.90K | -393.70K | -363.70K | -368.90K | -416.50K |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -127.30K | -129.20K | -544.90K | -552.70K | -4.09M |
| Foreign Exchange rate Adjustments | -300.00 | -300.00 | 300.00 | 300.00 | -1.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 507.40K | 515.00K | -71.00K | -72.10K | -157.00K |
